PancraGEN®

About Interpace Biosciences

Interpace Biosciences is a commercial-stage molecular diagnostics company with a mission to deliver evidence-based tests for the early diagnosis and risk assessment of cancer. Its primary achievement is the development and commercialization of a complementary genomic and microRNA testing platform for thyroid nodules, which has established clinical utility in guiding patient management. The company's strategy is to leverage its integrated bioinformatics and commercial capabilities to dominate its niche in thyroid diagnostics while exploring research collaborations for future test development. Following the 2022 sale of its pharma services division, Interpace is now a focused, independent diagnostics entity.

Therapeutic Areas